Greenway Announces International Supply Agreement with 4C LABS

Rhea-AI Summary

Greenway Greenhouse Cannabis Corporation (OTCQB: GWAYF) has secured a significant international supply agreement with 4C LABS, a prominent UK-based medical cannabis company. Through this partnership, Greenway will supply high-quality dried flower products to the UK market, leveraging 4C LABS' established distribution network and import licenses.

The agreement positions Greenway to tap into rapidly growing international markets, potentially offering better margins compared to the Canadian domestic market. Additionally, the Company announced the issuance of 337,507 common shares to Abingdon Capital Corporation at prices between $0.20 and $0.29 per share as compensation for corporate-finance advisory services.

Positive

• Entry into UK medical cannabis market through partnership with established distributor
• Potential for higher margins compared to Canadian domestic market
• Access to 4C LABS' existing pharmacy network in UK & Channel Islands

Negative

• Share issuance may lead to dilution for existing shareholders

KINGSVILLE, ON, July 31, 2025 /PRNewswire/ - Greenway Greenhouse Cannabis Corporation (CSE: GWAY) (OTCQB: GWAYF) ("Greenway" or the "Company"), a cultivator of high-quality greenhouse cannabis for the Canadian market, has entered into a supply agreement with 4C LABS, a leading medical cannabis company located in the United Kingdom, focused on providing patients with world class medical cannabis products. 

Through the agreement the Company expects to supply high-quality, dried flower product to 4C LABS, a leading importer and distributor of cannabis-based pharmaceuticals in the United Kingdom.

"We have met with many international groups looking for strong, consistent cannabis for medical use, as Canadian cannabis is seen as the gold standard for quality, safety and value. For Greenway, working with international partners opens us up to the fastest growing markets around the world, which should provide better margins than the current Canadian domestic market," said Carl Mastronardi, President of Greenway. "The team at 4C LABS impressed us with their local distribution system and drive to ensure only the best cannabis is used in their supply chain. Our product is perfectly suited to help them deliver on their unique value proposition to UK patients. We are excited about the prospect of seeing the product we put so much hard work into enjoyed by people around the world."

"We are impressed with the capabilities and company culture at Greenway" said Greg Dobbin, CEO of 4C LABS, "Greenway has developed into a premier medical cannabis grower, a result of decades of experience with greenhouse growing. They offer outstanding medical cannabis products at a very competitive price, which the patients of the UK will appreciate. We are excited to add Greenway to the 4C LABS product line."

Issuance of Shares

The Company is pleased to announce that, pursuant to its engagement letter dated June 4, 2024, with Abingdon Capital Corporation, an arm's length consultant (the "Consultant"), the Company has issued the Consultant and its assignees an aggregate of 337,507 common shares in the capital of the Company (the "Common Shares") at deemed prices between $0.20 and $0.29 per Common Share. The Common Shares were issued in satisfaction of a portion of the monthly work fee owed to the Consultant as consideration for the provision of corporate-finance advisory services. All Common Shares issued will be subject to a hold period of four months and a day from the date of issuance in accordance with applicable CSE policies and Canadian securities laws.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities in the United States nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "1933 Act"), or any state securities laws and may not be offered or sold in the United States unless registered under the 1933 Act and any applicable securities laws of any state of the United States or an applicable exemption from the registration requirements is available.

About 4C LABS Ltd.

4C LABS Ltd. is a privately held Canadian medical cannabis company focusing on providing UK pharmacies, clinics and patients with world class medical cannabis products at an affordable price. 4C LABS has import and distribution licenses in the UK and a wide network of pharmacies in the UK & Channel Islands. 4C LABS carries a full product line of medical cannabis from a selected network of trusted international cultivation partners. For more information, please visit www.4clabs.co.

About Greenway

Greenway Greenhouse Cannabis Corporation is a federally licensed cultivator for the Canadian cannabis marketplace. Greenway is headquartered in Kingsville, Ontario, and leverages its agriculture and cannabis expertise in its aspiration to be a leading cannabis cultivator in Canada. More information can be found on Greenway.ca and updates can be followed on Instagram, Twitter, Facebook, and LinkedIn.

Cautionary Note Regarding Forward-Looking Statements

This news release contains forward-looking statements that constitute forward-looking information (collectively, "forward-looking statements") within the meaning of applicable Canadian securities legislation. All statements in this news release that are not purely historical statements of fact are forward-looking statements and the Company's beliefs, plans, expectations, future, strategy, objectives, goals and targets, the development of future operations, and orientations regarding the future as of the date of this news release. Although the Company believes that such statements are reasonable and reflect expectations of future developments and other factors which management believes to be reasonable and relevant, the Company can give no assurance that such expectations will prove to be correct. Forward- looking statements are typically identified by words such as: "believes", "expects", "aim", "anticipates", "intends", "estimates", "plans", "may", "should", "would", "will", "potential", "scheduled" or variations of such words and phrases and similar expressions, which, by their nature, refer to future events or results that may, could, would, might or will occur or be taken or achieved.

Forward-looking statements involve known and unknown risks, assumptions, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking statements, and includes those risks described in the Company's final prospectus dated September 3, 2021, a copy of which is available under the Company's profile at www.sedarplus.ca. Forward-looking statements are made as of the date of this news release and, unless required by applicable law, the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements.

View original content to download multimedia:https://www.prnewswire.com/news-releases/greenway-announces-international-supply-agreement-with-4c-labs-302518038.html

SOURCE Greenway Greenhouse Cannabis Corporation

FAQ

What is the new supply agreement between Greenway (GWAYF) and 4C LABS?

Greenway has entered into an agreement to supply high-quality dried flower cannabis products to 4C LABS, a leading medical cannabis distributor in the United Kingdom.

How many shares did Greenway (GWAYF) issue to Abingdon Capital?

Greenway issued 337,507 common shares at prices between $0.20 and $0.29 per share to Abingdon Capital Corporation and its assignees.

What are the potential benefits of the UK supply agreement for Greenway (GWAYF)?

The agreement provides access to faster-growing international markets with potentially better margins than the Canadian domestic market, while leveraging 4C LABS' established UK distribution system.

Who is 4C LABS and what is their role in the UK cannabis market?

4C LABS is a privately held Canadian medical cannabis company with import and distribution licenses in the UK, focusing on providing UK pharmacies, clinics, and patients with medical cannabis products through their extensive pharmacy network.